Drugs facing NCE-1 in 2028
1. Alyftrek patent expiration
ALYFTREK's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8754224 | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(1 year, 1 month from now) | |
| US11639347 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Apr, 2027
(1 year, 5 months from now) | |
| US10239867 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Apr, 2027
(1 year, 5 months from now) | |
| US7645789 | VERTEX PHARMS INC | Indole derivatives as CFTR modulators |
May, 2027
(1 year, 6 months from now) | |
| USRE50453 | VERTEX PHARMS INC | NA |
May, 2027
(1 year, 6 months from now) | |
| US8623905 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
May, 2027
(1 year, 6 months from now) | |
| US7495103 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
May, 2027
(1 year, 6 months from now) | |
| US7776905 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Jun, 2027
(1 year, 7 months from now) | |
| US9181192 | VERTEX PHARMS INC | Deuterated CFTR potentiators |
May, 2032
(6 years from now) | |
| US8865902 | VERTEX PHARMS INC | Deuterated CFTR potentiators |
May, 2032
(6 years from now) | |
| US9512079 | VERTEX PHARMS INC | Deuterated CFTR potentiators |
May, 2032
(6 years from now) | |
| US10047053 | VERTEX PHARMS INC | Deuterated CFTR potentiators |
May, 2032
(6 years from now) | |
| US11066417 | VERTEX PHARMS INC | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators |
Feb, 2039
(13 years from now) | |
| US11873300 | VERTEX PHARMS INC | Crystalline forms of CFTR modulators |
Aug, 2040
(14 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8629162 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Jun, 2025
(4 months ago) | |
| US8354427 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Jul, 2026
(8 months from now) | |
| US9670163 | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(1 year, 1 month from now) | |
| US8410274 | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(1 year, 1 month from now) | |
| US9931334 | VERTEX PHARMS INC | Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(1 year, 1 month from now) | |
| US10022352 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Apr, 2027
(1 year, 5 months from now) | |
| US9974781 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Apr, 2027
(1 year, 5 months from now) | |
| US8598181 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
May, 2027
(1 year, 6 months from now) | |
| US8324242 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Aug, 2027
(1 year, 9 months from now) | |
| US8415387 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Nov, 2027
(2 years from now) | |
| US11564916 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Aug, 2029
(3 years from now) | |
| US10646481 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Aug, 2029
(3 years from now) | |
| US10081621 | VERTEX PHARMS INC | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
Mar, 2031
(5 years from now) | |
| US11578062 | VERTEX PHARMS INC | Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
Mar, 2031
(5 years from now) | |
| US9012496 | VERTEX PHARMS INC | Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof |
Jul, 2033
(7 years from now) | |
| US10058546 | VERTEX PHARMS INC | Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxo1-5-y1)-N-(1-(2,3-dihydroxypropy1)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-y1)-1H-indol-5-y1) cyclopropanecarbox-amide and administration thereof |
Jul, 2033
(7 years from now) | |
| US10206877 | VERTEX PHARMS INC | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases |
Apr, 2035
(9 years from now) | |
| US11951212 | VERTEX PHARMS INC | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases |
Apr, 2035
(9 years from now) | |
| US11866450 | VERTEX PHARMS INC | Modulators of Cystic Fibrosis Transmembrane Conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators |
Feb, 2039
(13 years from now) | |
| US12186306 | VERTEX PHARMS INC | Methods of treatment for cystic fibrosis |
Jan, 2043
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 20, 2029 |
Drugs and Companies using DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM ingredient
NCE-1 date: 20 December, 2028
Market Authorisation Date: 20 December, 2024
Treatment: Treatment of a moderate to mild clinical phenotype of cf in patients aged 6 years and older who have at least one f508del mutation or another responsive mutation in the cftr gene with a pharmaceutical...
Dosage: TABLET
More Information on Dosage
ALYFTREK family patents
2. Aqneursa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11400067 | INTRABIO | Pharmaceutical compositions and uses directed to lysosomal storage disorders |
Apr, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 24, 2029 |
| Orphan Drug Exclusivity(ODE-498) | Sep 24, 2031 |
Drugs and Companies using LEVACETYLLEUCINE ingredient
NCE-1 date: 24 September, 2028
Market Authorisation Date: 24 September, 2024
Treatment: Use of levacetylleucine for treatment of neurological manifestations of niemann-pick disease type-c (npc)
Dosage: FOR SUSPENSION
More Information on Dosage
AQNEURSA family patents
3. Attruby patent
expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9642838 | BRIDGEBIO PHARMA | Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions |
May, 2031
(5 years from now) | |
| US10513497 | BRIDGEBIO PHARMA | Process for preparing AG-10, its intermediates, and salts thereof |
Feb, 2038
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10398681 | BRIDGEBIO PHARMA | Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions |
May, 2031
(5 years from now) | |
| US9169214 | BRIDGEBIO PHARMA | Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions |
May, 2031
(5 years from now) | |
| US8877795 | BRIDGEBIO PHARMA | Identification of stabilizers of multimeric proteins |
May, 2031
(5 years from now) | |
| US10842777 | BRIDGEBIO PHARMA | Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions |
May, 2031
(5 years from now) | |
| US9913826 | BRIDGEBIO PHARMA | Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions |
May, 2031
(5 years from now) | |
| US11919865 | BRIDGEBIO PHARMA | Processes for preparing AG-10, its intermediates, and salts thereof |
Feb, 2038
(12 years from now) | |
| US12070449 | BRIDGEBIO PHARMA | Methods of treating TTR amyloidosis using AG10 |
Mar, 2039
(13 years from now) | |
| US11058668 | BRIDGEBIO PHARMA | Methods of treating TTR amyloidosis using AG10 |
Mar, 2039
(13 years from now) | |
| US12005043 | BRIDGEBIO PHARMA | Formulations of AG10 |
Aug, 2039
(13 years from now) | |
| US11260047 | BRIDGEBIO PHARMA | Formulations of AG10 |
Aug, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 22, 2029 |
| Orphan Drug Exclusivity(ODE-506) | Nov 22, 2031 |
Drugs and Companies using ACORAMIDIS HYDROCHLORIDE ingredient
NCE-1 date: 22 November, 2028
Market Authorisation Date: 22 November, 2024
Treatment: Treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (attr-cm)
Dosage: TABLET
More Information on Dosage
ATTRUBY family patents
4. Cobenfy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10238643 | BRISTOL-MYERS | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
Jul, 2030
(4 years from now) | |
| US10695339 | BRISTOL-MYERS | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
Jul, 2030
(4 years from now) | |
| US10369144 | BRISTOL-MYERS | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
Jul, 2030
(4 years from now) | |
| US10369143 | BRISTOL-MYERS | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
Jul, 2030
(4 years from now) | |
| US10265311 | BRISTOL-MYERS | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
Jul, 2030
(4 years from now) | |
| US10925832 | BRISTOL-MYERS | Compositions and methods for treatment of disorders ameliorated by muscarinic receptor activation |
Sep, 2039
(13 years from now) | |
| US11452692 | BRISTOL-MYERS | Compositions and methods for treating disorders ameliorated by muscarinic receptor activation |
Sep, 2039
(13 years from now) | |
| US11890378 | BRISTOL-MYERS | Compositions and methods for treating disorders ameliorated by muscarinic receptor activation |
Sep, 2039
(13 years from now) | |
| US11471413 | BRISTOL-MYERS | Compositions and methods for treating disorders ameliorated by muscarinic receptor activation |
Sep, 2039
(13 years from now) | |
| US10933020 | BRISTOL-MYERS | Compositions and methods for treating disorders ameliorated by muscarinic receptor activation |
Sep, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 26, 2029 |
Drugs and Companies using TROSPIUM CHLORIDE; XANOMELINE TARTRATE ingredient
NCE-1 date: 26 September, 2028
Market Authorisation Date: 26 September, 2024
Treatment: Treatment of schizophrenia in adults
Dosage: CAPSULE
More Information on Dosage
COBENFY family patents
5. Crenessity patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12128033 | NEUROCRINE | Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine |
Jun, 2041
(15 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10905690 | NEUROCRINE | Treatment of congenital adrenal hyperplasia |
Jan, 2035
(9 years from now) | |
| US11311544 | NEUROCRINE | Treatment of congenital adrenal hyperplasia |
Jan, 2035
(9 years from now) | |
| US11730739 | NEUROCRINE | Treatment of congenital adrenal hyperplasia |
Jan, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 13, 2029 |
| Orphan Drug Exclusivity(ODE-503) | Dec 13, 2031 |
Drugs and Companies using CRINECERFONT ingredient
NCE-1 date: 13 December, 2028
Market Authorisation Date: 13 December, 2024
Treatment: Adjunctive treatment of classic congenital adrenal hyperplasia (cah)
Dosage: CAPSULE; SOLUTION
More Information on Dosage
CRENESSITY family patents
6. Duvyzat patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7329689 | ITALFARMACO SPA | Monohydrate hydrochloride of the 4-hydroxycarbamoyl-phenyl)-carbamic acid (6-diethylaminomethyl-naphtalen-2-yl) ester |
Jan, 2026
(2 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9421184 | ITALFARMACO SPA | Diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride for use in the treatment of muscular dystrophy |
Feb, 2032
(6 years from now) | |
| US9867799 | ITALFARMACO SPA | Diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride for use in the treatment of muscular dystrophy |
Feb, 2032
(6 years from now) | |
| US10688047 | ITALFARMACO SPA | Physically and chemically stable oral suspensions of givinostat |
Oct, 2036
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 21, 2029 |
| Orphan Drug Exclusivity(ODE-473) | Mar 21, 2031 |
Drugs and Companies using GIVINOSTAT HYDROCHLORIDE ingredient
NCE-1 date: 21 March, 2028
Market Authorisation Date: 21 March, 2024
Treatment: A method for the treatment of duchenne muscular dystrophy (dmd) using givinostat
Dosage: SUSPENSION
More Information on Dosage
DUVYZAT family patents
7. Ensacove patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8551995 | XCOVERY | Kinase inhibitor compounds |
Feb, 2029
(3 years from now) | |
| US9296724 | XCOVERY | Substituted pyridazinecarboxamides as kinase inhibitors |
Jun, 2029
(3 years from now) | |
| US9126947 | XCOVERY | Substituted pyridazine carboxamide compounds |
Nov, 2031
(6 years from now) | |
| US10899744 | XCOVERY | Crystalline form of compound suppressing protein kinase activity, and application thereof |
Jun, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2029 |
Drugs and Companies using ENSARTINIB HYDROCHLORIDE ingredient
NCE-1 date: 18 December, 2028
Market Authorisation Date: 18 December, 2024
Treatment: Treatment of adult patients with anaplastic lymphoma kinase (alk)-positive locally advanced or metastatic non-small cell lung cancer (nsclc) who have not previously received an alk-inhibitor
Dosage: CAPSULE
More Information on Dosage
ENSACOVE family patents
8. Fetroja patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9238657 | SHIONOGI INC | Cephalosporin having catechol group |
Nov, 2033
(8 years from now) | |
| US10004750 | SHIONOGI INC | Salt of cephalosporin derivative, its crystalline solid and a method of manufacturing thereof |
Sep, 2035
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9949982 | SHIONOGI INC | Preparation containing cephalosporin having a catechol moiety |
Sep, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-844) | Sep 25, 2023 |
| New Chemical Entity Exclusivity(NCE) | Nov 14, 2024 |
| Generating Antibiotic Incentives Now(GAIN) | Nov 14, 2029 |
Drugs and Companies using CEFIDEROCOL SULFATE TOSYLATE ingredient
NCE-1 date: 14 November, 2028
Market Authorisation Date: 14 November, 2019
Treatment: Method of treating hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (habp/vabp) comprising administering cefiderocol sulfate tosylate
Dosage: POWDER
More Information on Dosage
FETROJA family patents
9. Flyrcado patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9161997 | GE HLTHCARE | Contrast agents for myocardial perfusion imaging |
Feb, 2026
(3 months from now) | |
| US7344702 | GE HLTHCARE | Contrast agents for myocardial perfusion imaging |
May, 2026
(6 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8226929 | GE HLTHCARE | Contrast agents for myocardial perfusion imaging |
Jun, 2028
(2 years from now) | |
| US9603951 | GE HLTHCARE | Methods and apparatus for synthesizing imaging agents, and intermediates thereof |
May, 2031
(5 years from now) | |
| US8936777 | GE HLTHCARE | Methods and apparatus for synthesizing imaging agents, and intermediates thereof |
Jun, 2031
(5 years from now) | |
| US9687571 | GE HLTHCARE | Stabilization of radiopharmaceutical compositions using ascorbic acid |
Nov, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 27, 2029 |
Drugs and Companies using FLURPIRIDAZ F-18 ingredient
NCE-1 date: 27 September, 2028
Market Authorisation Date: 27 September, 2024
Treatment: Method of positron emission tomography (pet) for cardiac imaging
Dosage: SOLUTION
More Information on Dosage
FLYRCADO family patents
10. Ibrance patent expiration
IBRANCE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6936612 | PFIZER | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones |
Jan, 2023
(2 years ago) | |
| US7208489 | PFIZER | 2-(pyridin-2-ylamino)-pyrido [2,3-d]pyrimidin-7-ones |
Jan, 2023
(2 years ago) | |
| USRE47739 | PFIZER | 2-(pyridin-2-ylamino)-pyrido[2,3-D]pyrimidin-7-ones |
Mar, 2027
(1 year, 4 months from now) | |
| US10723730 | PFIZER | Solid forms of a selective CDK4/6 inhibitor |
Feb, 2034
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7456168 | PFIZER | 2-(pyridin-2-ylamino)-pyrido[2,3, d]pyrimidin-7-ones |
Jan, 2023
(2 years ago) | |
|
USRE47739 (Pediatric) | PFIZER | NA |
Sep, 2027
(1 year, 10 months from now) | |
|
US10723730 (Pediatric) | PFIZER | NA |
Aug, 2034
(8 years from now) | |
| US11065250 | PFIZER | Solid dosage forms of palbociclib |
Aug, 2036
(10 years from now) | |
|
US11065250 (Pediatric) | PFIZER | NA |
Feb, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-725) | Feb 19, 2019 |
| New Chemical Entity Exclusivity(NCE) | Feb 03, 2020 |
| M(M-14) | Sep 16, 2028 |
| Pediatric Exclusivity(PED) | Mar 16, 2029 |
Drugs and Companies using PALBOCICLIB ingredient
NCE-1 date: 16 March, 2028
Market Authorisation Date: 03 February, 2015
Treatment: Palbociclib for hr-pos. her2-neg. advanced or metastatic breast cancer in combo with an aromatase inhibitor in pts as initial endocrine-based therapy or with fulvestrant with disease progression after...
Dosage: TABLET
How can I launch a generic of IBRANCE before it's drug patent expiration?
More Information on Dosage
IBRANCE family patents
11. Iqirvo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7943661 | IPSEN | Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof |
Sep, 2024
(1 year, 1 month ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7632870 | IPSEN | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof |
Sep, 2024
(1 year, 1 month ago) | |
| US11850223 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(11 years from now) | |
| US11331292 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(11 years from now) | |
| US11857523 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(11 years from now) | |
| US12295927 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(11 years from now) | |
| US12233038 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(11 years from now) | |
| US12310935 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(11 years from now) | |
| US12295928 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(11 years from now) | |
| US11185519 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 10, 2029 |
| Orphan Drug Exclusivity(ODE-486) | Jun 10, 2031 |
Drugs and Companies using ELAFIBRANOR ingredient
NCE-1 date: 10 June, 2028
Market Authorisation Date: 10 June, 2024
Treatment: Treatment of primary biliary cholangitis (pbc); Treatment of primary biliary cholangitis (pbc) in combination with ursodeoxycholic acid (udca) in adults who have had an inadequate response to udca, or...
Dosage: TABLET
More Information on Dosage
IQIRVO family patents
12. Itovebi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8242104 | GENENTECH INC | Benzoxazepin P13K inhibitor compounds and methods of use |
Sep, 2030
(4 years from now) | |
| US9650393 | GENENTECH INC | Benzoxazepin oxazolidinone compounds and methods of use |
Jul, 2036
(10 years from now) | |
| US10851091 | GENENTECH INC | Benzoxazepin oxazolidinone compounds and methods of use |
Jul, 2036
(10 years from now) | |
| US11028100 | GENENTECH INC | Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production |
Apr, 2038
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8343955 | GENENTECH INC | Benzoxazepin PI3K inhibitor compounds and methods of use |
Sep, 2030
(4 years from now) | |
| US11760753 | GENENTECH INC | Benzoxazepin oxazolidinone compounds and methods of use |
Jul, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 10, 2029 |
Drugs and Companies using INAVOLISIB ingredient
NCE-1 date: 10 October, 2028
Market Authorisation Date: 10 October, 2024
Treatment: Combination with palbociclib and fulvestrant for treatment of adults with endocrine-resistant pik3ca-mutated hr-positive her2-negative locally advanced or metastatic breast cancer following recurrence...
Dosage: TABLET
More Information on Dosage
ITOVEBI family patents
13. Jakafi patent expiration
JAKAFI's oppositions filed in EPO
JAKAFI IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9662335 | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors |
Dec, 2026
(1 year, 1 month from now) | |
| US7598257 | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
Dec, 2027
(2 years from now) | |
| US8415362 | INCYTE CORP | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
Dec, 2027
(2 years from now) | |
| US8722693 | INCYTE CORP | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9079912 | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors |
Dec, 2026
(1 year, 1 month from now) | |
| US9814722 | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors |
Dec, 2026
(1 year, 1 month from now) | |
|
US9814722 (Pediatric) | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors |
Jun, 2027
(1 year, 7 months from now) | |
|
US9079912 (Pediatric) | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors |
Jun, 2027
(1 year, 7 months from now) | |
| US8829013 | INCYTE CORP | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(2 years from now) | |
| US10016429 | INCYTE CORP | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(2 years from now) | |
| US8822481 | INCYTE CORP | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(2 years from now) | |
|
US8415362 (Pediatric) | INCYTE CORP | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
Jun, 2028
(2 years from now) | |
|
US7598257 (Pediatric) | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
Jun, 2028
(2 years from now) | |
|
US10016429 (Pediatric) | INCYTE CORP | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Dec, 2028
(3 years from now) | |
|
US8822481 (Pediatric) | INCYTE CORP | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Dec, 2028
(3 years from now) | |
|
US8829013 (Pediatric) | INCYTE CORP | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Dec, 2028
(3 years from now) | |
|
US8722693 (Pediatric) | INCYTE CORP | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Dec, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 16, 2016 |
| New Indication(I-699) | Dec 04, 2017 |
| Orphan Drug Exclusivity(ODE) | Nov 16, 2018 |
| Orphan Drug Exclusivity(ODE-19) | Nov 16, 2018 |
| Orphan Drug Exclusivity(ODE-79) | Dec 04, 2021 |
| New Indication(I-799) | May 24, 2022 |
| New Indication(I-872) | Sep 22, 2024 |
| M(M-285) | Dec 19, 2025 |
| Orphan Drug Exclusivity(ODE-238) | May 24, 2026 |
| Orphan Drug Exclusivity(ODE-373) | Sep 22, 2028 |
| Pediatric Exclusivity(PED) | Mar 22, 2029 |
Drugs and Companies using RUXOLITINIB PHOSPHATE ingredient
NCE-1 date: 22 March, 2028
Market Authorisation Date: 16 November, 2011
Treatment: For treatment of steroid-refractory acute graft-versus-host disease (agvhd); For treatment of polycythemia vera (pv) in patients who have had an inadequate response to or are intolerant of hydroxyurea...
Dosage: TABLET
How can I launch a generic of JAKAFI before it's drug patent expiration?
More Information on Dosage
JAKAFI family patents
14. Lazcluze patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9593098 | JANSSEN BIOTECH | Compounds and compositions for modulating EGFR mutant kinase activities |
Oct, 2035
(9 years from now) | |
| US11453656 | JANSSEN BIOTECH | Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same |
Apr, 2038
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11981659 | JANSSEN BIOTECH | Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same |
Apr, 2038
(12 years from now) | |
| US11879013 | JANSSEN BIOTECH | Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors |
May, 2040
(14 years from now) | |
| US12138351 | JANSSEN BIOTECH | Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof |
Apr, 2041
(15 years from now) | |
| US11850248 | JANSSEN BIOTECH | Therapies with 3rd generation EGFR tyrosine kinase inhibitors |
Aug, 2041
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 19, 2029 |
Drugs and Companies using LAZERTINIB MESYLATE ingredient
NCE-1 date: 19 August, 2028
Market Authorisation Date: 19 August, 2024
Treatment: First-line treatment of adults with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr exon 19 deletions or exon 21 l858r substitution mutations, in combination with amivantam...
Dosage: TABLET
More Information on Dosage
LAZCLUZE family patents
15. Leqselvi patent expiration
LEQSELVI IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12247034 | SUN PHARM INDS INC | Crystalline form of deuruxolitinib phosphate |
May, 2044
(18 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12076323 | SUN PHARM INDS INC | Treatment of hair loss disorders with deuterated JAK inhibitors |
May, 2037
(11 years from now) | |
| US10561659 | SUN PHARM INDS INC | Treatment of hair loss disorders with deuterated JAK inhibitors |
May, 2037
(11 years from now) | |
| US11919907 | SUN PHARM INDS INC | Deuterated JAK inhibitor and uses thereof |
May, 2041
(15 years from now) | |
| US12285432 | SUN PHARM INDS INC | Treatment of hair loss disorders with deuterated JAK inhibitors |
Aug, 2042
(16 years from now) | |
| US12364699 | SUN PHARM INDS INC | NA |
Oct, 2044
(18 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 25, 2029 |
Drugs and Companies using DEURUXOLITINIB PHOSPHATE ingredient
NCE-1 date: 25 July, 2028
Market Authorisation Date: 25 July, 2024
Treatment: Treatment of adult patients with alopecia areata
Dosage: TABLET
More Information on Dosage
LEQSELVI family patents
16. Livdelzi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7301050 | GILEAD SCIENCES INC | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
Aug, 2026
(9 months from now) | |
| US7709682 | GILEAD SCIENCES INC | Lysine salts of 4-((phenoxyalkyl)thio)-phenoxyacetic acid derivatives |
Sep, 2026
(10 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11596614 | GILEAD SCIENCES INC | Treatment of intrahepatic cholestatic diseases |
Mar, 2035
(9 years from now) | |
| US11406611 | GILEAD SCIENCES INC | Treatment of intrahepatic cholestatic diseases |
Mar, 2035
(9 years from now) | |
| US9486428 | GILEAD SCIENCES INC | Treatment of intrahepatic cholestatic diseases |
Mar, 2035
(9 years from now) | |
| US10272058 | GILEAD SCIENCES INC | Treatment of intrahepatic cholestatic diseases |
Mar, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 14, 2029 |
| Orphan Drug Exclusivity(ODE-486) | Aug 14, 2031 |
Drugs and Companies using SELADELPAR LYSINE ingredient
NCE-1 date: 14 August, 2028
Market Authorisation Date: 14 August, 2024
Treatment: Treatment of primary biliary cholangitis (pbc)
Dosage: CAPSULE
More Information on Dosage
LIVDELZI family patents
17. Lumisight patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11592396 | LUMICELL | Methods and systems for spatially identifying abnormal cells |
Sep, 2030
(4 years from now) | |
| US9763577 | LUMICELL | Imaging agent for detection of diseased cells |
Sep, 2034
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9155471 | LUMICELL | Methods and systems for spatially identifying abnormal cells |
Oct, 2031
(5 years from now) | |
| US9032965 | LUMICELL | Methods and system for image guided cell ablation with microscopic resolution |
Dec, 2031
(6 years from now) | |
| US10285759 | LUMICELL | Methods and system for image guided cell ablation with microscopic resolution |
Dec, 2031
(6 years from now) | |
| US9532835 | LUMICELL | Methods and system for image guided cell ablation with microscopic resolution |
Dec, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 17, 2029 |
Drugs and Companies using PEGULICIANINE ACETATE ingredient
NCE-1 date: 17 April, 2028
Market Authorisation Date: 17 April, 2024
Treatment: A method comprising administering pegulicianine to a human and obtaining an image of a tumor bed after tumor resection to distinguish in situ cancer cells from healthy cells
Dosage: POWDER
More Information on Dosage
LUMISIGHT family patents
18. Miplyffa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9884058 | ZEVRA DENMARK | Use of Hsp70 as a regulator of enzymatic activity |
Jun, 2029
(3 years from now) | |
| US9289472 | ZEVRA DENMARK | Use of HSP70 as a regulator of enzymatic activity |
Aug, 2029
(3 years from now) | |
| US11045460 | ZEVRA DENMARK | Use of Hsp70 as a regulator of enzymatic activity |
Aug, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 20, 2029 |
| Orphan Drug Exclusivity(ODE-496) | Sep 20, 2031 |
Drugs and Companies using ARIMOCLOMOL CITRATE ingredient
NCE-1 date: 20 September, 2028
Market Authorisation Date: 20 September, 2024
Treatment: Use of arimoclomol, in combination with miglustat, for treatment of neurological manifestations of niemann-pick disease type c (npc)
Dosage: CAPSULE
More Information on Dosage
MIPLYFFA family patents
19. Ohtuvayre patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9062047 | VERONA PHARMA | Crystalline form of pyrimido[6,1-A] isoquinolin-4-one compound |
Aug, 2031
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10945950 | VERONA PHARMA | Liquid inhalation formulation comprising RPL554 |
Sep, 2035
(9 years from now) | |
| US9956171 | VERONA PHARMA | Liquid inhalation formulation comprising RPL554 |
Sep, 2035
(9 years from now) | |
| US12409180 | VERONA PHARMA | NA |
Feb, 2043
(17 years from now) | |
| US12251384 | VERONA PHARMA | Particulate composition |
Jun, 2044
(18 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 26, 2029 |
Drugs and Companies using ENSIFENTRINE ingredient
NCE-1 date: 26 June, 2028
Market Authorisation Date: 26 June, 2024
Treatment: For the maintenance treatment of chronic obstructive pulmonary disease (copd) in adult patients
Dosage: SUSPENSION
More Information on Dosage
OHTUVAYRE family patents
20. Ojemda patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8293752 | DAY ONE BIOPHARMS | Compounds useful as Raf kinase inhibitors |
Aug, 2031
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10426782 | DAY ONE BIOPHARMS | Pharmaceutical formulations of a pan-RAF kinase inhibitor and processes for their preparation |
Jun, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 23, 2029 |
| Orphan Drug Exclusivity(ODE-478) | Apr 23, 2031 |
Drugs and Companies using TOVORAFENIB ingredient
NCE-1 date: 23 April, 2028
Market Authorisation Date: 23 April, 2024
Treatment: NA
Dosage: TABLET; FOR SUSPENSION
More Information on Dosage
OJEMDA family patents
21. Rapiblyk patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10722516 | AOP ORPHAN | NA |
Apr, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 22, 2029 |
Drugs and Companies using LANDIOLOL HYDROCHLORIDE ingredient
NCE-1 date: 22 November, 2028
Market Authorisation Date: 22 November, 2024
Treatment: A method of reducing the heart rate of a subject suffering from supraventricular tachycardia, wherein landiolol is administered parenterally at a constant dose of more than 20 mcg/kg/min for 2-20 hour...
Dosage: POWDER
More Information on Dosage
RAPIBLYK family patents
22. Recarbrio patent expiration
Can you believe RECARBRIO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8487093 | MSD MERCK CO | β-lactamase inhibitors |
Mar, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 16, 2024 |
| Generating Antibiotic Incentives Now(GAIN) | Jul 16, 2029 |
Drugs and Companies using CILASTATIN SODIUM; IMIPENEM; RELEBACTAM ingredient
NCE-1 date: 16 July, 2028
Market Authorisation Date: 16 July, 2019
Treatment: Treatment of complicated urinary tract infections, including pyelonephritis (cuti)
Dosage: POWDER
More Information on Dosage
RECARBRIO family patents
23. Revuforj patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10683302 | SYNDAX | Inhibitors of the menin-MLL interaction |
Jun, 2037
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11479557 | SYNDAX | Inhibitors of the menin-MLL interaction |
Jun, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 15, 2029 |
| Orphan Drug Exclusivity(ODE-502) | Nov 15, 2031 |
| Orphan Drug Exclusivity(ODE-504) | Nov 15, 2031 |
| Orphan Drug Exclusivity(ODE-505) | Nov 15, 2031 |
Drugs and Companies using REVUMENIB CITRATE ingredient
NCE-1 date: 15 November, 2028
Market Authorisation Date: 15 November, 2024
Treatment: Treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2a gene (kmt2a) translocation in adult and pediatric patients 1 year and older
Dosage: TABLET
More Information on Dosage
REVUFORJ family patents
24. Rezdiffra patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7452882 | MADRIGAL | Thyroid hormone analogs |
Sep, 2026
(10 months from now) | |
| US11564926 | MADRIGAL | Methods of synthesizing thyroid hormone analogs and polymorphs thereof |
Sep, 2033
(7 years from now) | |
| US9266861 | MADRIGAL | Method of synthesizing thyroid hormone analogs and polymorphs thereof |
Sep, 2033
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11986481 | MADRIGAL | Method of synthesizing thyroid hormone analogs and polymorphs thereof |
Sep, 2033
(7 years from now) | |
| US10376517 | MADRIGAL | Methods of synthesizing thyroid hormone analogs and polymorphs thereof |
Sep, 2033
(7 years from now) | |
| US12377104 | MADRIGAL | NA |
Feb, 2045
(19 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 14, 2029 |
Drugs and Companies using RESMETIROM ingredient
NCE-1 date: 14 March, 2028
Market Authorisation Date: 14 March, 2024
Treatment: Treatment of adults with noncirrhotic nonalcoholic steatohepatitis (nash) with moderate to advanced liver fibrosis (consistent with stages f2 to f3 fibrosis)
Dosage: TABLET
More Information on Dosage
REZDIFFRA family patents
25. Sofdra patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8147809 | BOTANIX SB | Soft anticholinergic esters |
Mar, 2027
(1 year, 4 months from now) | |
| US11566000 | BOTANIX SB | Crystalline form of sofpironium bromide and preparation method thereof |
May, 2040
(14 years from now) | |
| US11584715 | BOTANIX SB | Crystalline form of sofpironium bromide and preparation method thereof |
May, 2040
(14 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8628759 | BOTANIX SB | Soft anticholinergic esters |
Nov, 2026
(1 year, 15 days from now) | |
| US9492429 | BOTANIX SB | Method of dosing and use of soft anticholinergic esters |
Mar, 2034
(8 years from now) | |
| US10383846 | BOTANIX SB | Method of dosing and use of soft anticholinergic esters |
Mar, 2034
(8 years from now) | |
| US9895350 | BOTANIX SB | Method of dosing and use of soft anticholinergic esters |
Mar, 2034
(8 years from now) | |
| US9220707 | BOTANIX SB | Method of dosing and use of soft anticholinergic esters |
Mar, 2034
(8 years from now) | |
| US10947192 | BOTANIX SB | Formulation for soft anticholinergic analogs |
May, 2034
(8 years from now) | |
| US11084788 | BOTANIX SB | Formulation for soft anticholinergic analogs |
May, 2034
(8 years from now) | |
| US11052067 | BOTANIX SB | Formulation for soft anticholinergic analogs |
May, 2034
(8 years from now) | |
| US11034652 | BOTANIX SB | Formulation for soft anticholinergic analogs |
May, 2034
(8 years from now) | |
| US11026919 | BOTANIX SB | Formulation for soft anticholinergic analogs |
May, 2034
(8 years from now) | |
| US10961191 | BOTANIX SB | Formulation for soft anticholinergic analogs |
May, 2034
(8 years from now) | |
| US12398102 | BOTANIX SB | NA |
May, 2034
(8 years from now) | |
| US12357609 | BOTANIX SB | NA |
May, 2034
(8 years from now) | |
| US10952990 | BOTANIX SB | Formulation for soft anticholinergic analogs |
May, 2034
(8 years from now) | |
| US12156865 | BOTANIX SB | Formulation for soft anticholinergic analogs |
May, 2034
(8 years from now) | |
| US10959983 | BOTANIX SB | Formulation for soft anticholinergic analogs |
May, 2034
(8 years from now) | |
| US11123325 | BOTANIX SB | Formulation for soft anticholinergic analogs |
Jul, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 20, 2029 |
Drugs and Companies using SOFPIRONIUM BROMIDE ingredient
NCE-1 date: 20 June, 2028
Market Authorisation Date: 18 June, 2024
Treatment: Topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older
Dosage: GEL, METERED
More Information on Dosage
SOFDRA family patents
26. Tasigna patent expiration
TASIGNA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7169791 | NOVARTIS | Inhibitors of tyrosine kinases |
Jul, 2023
(2 years ago) | |
| US8415363 | NOVARTIS | Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
Jul, 2026
(8 months from now) | |
| US8163904 | NOVARTIS | Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide |
Aug, 2028
(2 years from now) | |
| US9061029 | NOVARTIS | Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity |
Apr, 2032
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7169791 | NOVARTIS | Inhibitors of tyrosine kinases |
Jul, 2023
(2 years ago) | |
|
US7169791 (Pediatric) | NOVARTIS | Inhibitors of tyrosine kinases |
Jan, 2024
(1 year, 9 months ago) | |
| US8389537 | NOVARTIS | Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
Jul, 2026
(8 months from now) | |
| US8501760 | NOVARTIS | Pharmaceutical compositions comprising nilotinib or its salt |
Jul, 2026
(8 months from now) | |
|
US8415363 (Pediatric) | NOVARTIS | Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
Jan, 2027
(1 year, 2 months from now) | |
|
US8501760 (Pediatric) | NOVARTIS | Pharmaceutical compositions comprising nilotinib or its salt |
Jan, 2027
(1 year, 2 months from now) | |
|
US8389537 (Pediatric) | NOVARTIS | Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
Jan, 2027
(1 year, 2 months from now) | |
| US8293756 | NOVARTIS | Pharmaceutical compositions comprising nilotinib hydrochloride monohydrate |
Sep, 2027
(1 year, 10 months from now) | |
|
US8293756 (Pediatric) | NOVARTIS | Pharmaceutical compositions comprising nilotinib hydrochloride monohydrate |
Mar, 2028
(2 years from now) | |
|
US8163904 (Pediatric) | NOVARTIS | Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide |
Feb, 2029
(3 years from now) | |
|
US9061029 (Pediatric) | NOVARTIS | Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity |
Oct, 2032
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 29, 2012 |
| New Indication(I-627) | Jun 17, 2014 |
| Orphan Drug Exclusivity(ODE) | Oct 29, 2014 |
| New Dosing Schedule(D-170) | Dec 22, 2020 |
| New Patient Population(NPP) | Mar 22, 2021 |
| Orphan Drug Exclusivity(ODE-171) | Mar 22, 2025 |
| Orphan Drug Exclusivity(ODE-172) | Mar 22, 2025 |
| Orphan Drug Exclusivity(ODE-380) | Sep 23, 2028 |
| Pediatric Exclusivity(PED) | Mar 23, 2029 |
Drugs and Companies using NILOTINIB HYDROCHLORIDE ingredient
NCE-1 date: 23 March, 2028
Market Authorisation Date: 22 March, 2018
Treatment: A method for the treatment of leukemias; Treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml); Treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml...
Dosage: CAPSULE
How can I launch a generic of TASIGNA before it's drug patent expiration?
More Information on Dosage
TASIGNA family patents
27. Tryvio patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8324232 | IDORSIA | 4-pyrimidinesulfamide derivative |
Sep, 2029
(3 years from now) | |
| US10919881 | IDORSIA | Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan |
Feb, 2038
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11174247 | IDORSIA | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases |
Nov, 2037
(12 years from now) | |
| US12297189 | IDORSIA | Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan |
Feb, 2038
(12 years from now) | |
| US11787782 | IDORSIA | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases |
Mar, 2038
(12 years from now) | |
| US11680058 | IDORSIA | Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan |
Jul, 2038
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 22, 2029 |
Drugs and Companies using APROCITENTAN ingredient
NCE-1 date: 22 March, 2028
Market Authorisation Date: 19 March, 2024
Treatment: Treatment of hypertension in combination with other antihypertensive drugs, including an angiotensin receptor blocker, to lower blood pressure in adult patients who are not adequately controlled on ot...
Dosage: TABLET
More Information on Dosage
TRYVIO family patents
28. Vafseo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8598210 | AKEBIA | Prolyl hydroxylase inhibitors and methods of use |
Jun, 2027
(1 year, 7 months from now) | |
| USRE47437 | AKEBIA | Prolyl hydroxylase inhibitors and methods of use |
Jun, 2027
(1 year, 7 months from now) | |
| US8343952 | AKEBIA | Prolyl hydroxylase inhibitors and methods of use |
Aug, 2027
(1 year, 9 months from now) | |
| US7811595 | AKEBIA | Prolyl hydroxylase inhibitors and methods of use |
Mar, 2028
(2 years from now) | |
| US10149842 | AKEBIA | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof |
Nov, 2034
(9 years from now) | |
| US9701636 | AKEBIA | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof |
Nov, 2034
(9 years from now) | |
| US11065237 | AKEBIA | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof |
Nov, 2034
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8940773 | AKEBIA | Prolyl hydroxylase inhibitors and methods of use |
Jun, 2027
(1 year, 7 months from now) | |
| US8323671 | AKEBIA | Prolyl hydroxylase inhibitors and methods of use |
Apr, 2028
(2 years from now) | |
| US11857543 | AKEBIA | Compositions and methods for treating anemia |
Jun, 2034
(8 years from now) | |
| US9987262 | AKEBIA | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof |
Nov, 2034
(9 years from now) | |
| US11844756 | AKEBIA | Compositions and methods for treating anemia |
Mar, 2036
(10 years from now) | |
| US11324734 | AKEBIA | Compositions and methods for treating anemia |
Mar, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 27, 2029 |
Drugs and Companies using VADADUSTAT ingredient
NCE-1 date: 27 March, 2028
Market Authorisation Date: 27 March, 2024
Treatment: Treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months
Dosage: TABLET
More Information on Dosage
VAFSEO family patents
29. Voranigo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10172864 | SERVIER | Therapeutically active compounds and their methods of use |
Jul, 2034
(8 years from now) | |
| US9579324 | SERVIER | Therapeutically active compounds and their methods of use |
Jul, 2034
(8 years from now) | |
| US11345677 | SERVIER | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same |
Jan, 2039
(13 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11844758 | SERVIER | Therapeutically active compounds and their methods of use |
Dec, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 06, 2029 |
| Orphan Drug Exclusivity(ODE-491) | Aug 06, 2031 |
Drugs and Companies using VORASIDENIB ingredient
NCE-1 date: 06 August, 2028
Market Authorisation Date: 06 August, 2024
Treatment: A method of treating a glioma characterized by an idhi mutation following surgery, wherein the glioma is grade 2 astrocytoma or oligodendroglioma; A method of treating a cancer characterized by an idh...
Dosage: TABLET
More Information on Dosage
VORANIGO family patents
30. Voydeya patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9796741 | ALEXION PHARMS INC | Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders |
Feb, 2035
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12076319 | ALEXION PHARMS INC | Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria |
Aug, 2038
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 29, 2029 |
| Orphan Drug Exclusivity(ODE-476) | Mar 29, 2031 |
Drugs and Companies using DANICOPAN ingredient
NCE-1 date: 29 March, 2028
Market Authorisation Date: 29 March, 2024
Treatment: Treatment of extravascular hemolysis (evh) in adults with paroxysmal nocturnal hemoglobinuria (pnh) as add-on therapy to ravulizumab or eculizumab
Dosage: TABLET
More Information on Dosage
VOYDEYA family patents
31. Xenleta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6753445 | HONG KONG | Pleuromutilin derivatives having antibacterial activity |
Jul, 2021
(4 years ago) | |
| US8153689 | HONG KONG | Pleuromutilin derivatives for the treatment of diseases mediated by microbes |
Mar, 2028
(2 years from now) | |
| US9120727 | HONG KONG | Process for the preparation of pleuromutilins |
May, 2031
(5 years from now) | |
| US8071643 | HONG KONG | Pleuromutilin derivatives for the treatment of diseases mediated by microbes |
Mar, 2033
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12121582 | HONG KONG | Injectable pharmaceutical formulations of lefamulin |
Jun, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 19, 2024 |
| Generating Antibiotic Incentives Now(GAIN) | Aug 19, 2029 |
Drugs and Companies using LEFAMULIN ACETATE ingredient
NCE-1 date: 19 August, 2028
Market Authorisation Date: 19 August, 2019
Treatment: Treatment of adults with community-acquired bacterial pneumonia caused by susceptible microorganisms
Dosage: TABLET; SOLUTION
More Information on Dosage
XENLETA family patents
32. Xolremdi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10953003 | X4 PHARMS | Methods for treating cancer |
Dec, 2036
(11 years from now) | |
| US10610527 | X4 PHARMS | Methods for treating immunodeficiency disease |
Dec, 2036
(11 years from now) | |
| US11219621 | X4 PHARMS | Methods for treating immunodeficiency disease |
Dec, 2036
(11 years from now) | |
| US12115156 | X4 PHARMS | Compositions of CXCR4 inhibitors and methods of preparation and use |
Dec, 2038
(13 years from now) | |
| US11045461 | X4 PHARMS | Compositions of CXCR4 inhibitors and methods of preparation and use |
Dec, 2038
(13 years from now) | |
| US10548889 | X4 PHARMS | Compositions of CXCR4 inhibitors and methods of preparation and use |
Dec, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 26, 2029 |
| Orphan Drug Exclusivity(ODE-480) | Apr 26, 2031 |
Drugs and Companies using MAVORIXAFOR ingredient
NCE-1 date: 26 April, 2028
Market Authorisation Date: 26 April, 2024
Treatment: Treatment of patients 12 years and older with warts, hypogammaglobulinemia, infections, and myelokathexis (whim) syndrome
Dosage: CAPSULE
More Information on Dosage
XOLREMDI family patents
33. Yorvipath patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8906847 | ASCENDIS PHARMA BONE | Prodrug comprising a drug linker conjugate |
Apr, 2031
(5 years from now) | |
| US11890326 | ASCENDIS PHARMA BONE | Controlled-release PTH compound |
Sep, 2037
(11 years from now) | |
| US11918628 | ASCENDIS PHARMA BONE | Controlled-release PTH compound |
Sep, 2037
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11759504 | ASCENDIS PHARMA BONE | PTH compounds with low peak-to-trough ratios |
Sep, 2037
(11 years from now) | |
| US11590207 | ASCENDIS PHARMA BONE | Dosage regimen for a controlled-release PTH compound |
Sep, 2037
(11 years from now) | |
| US11857603 | ASCENDIS PHARMA BONE | PTH compounds with low peak-to-trough ratios |
Sep, 2037
(11 years from now) | |
| US12295989 | ASCENDIS PHARMA BONE | Controlled-release PTH compound |
Sep, 2037
(11 years from now) | |
| US12403182 | ASCENDIS PHARMA BONE | NA |
Nov, 2042
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 09, 2027 |
| New Chemical Entity Exclusivity(NCE) | Aug 09, 2029 |
| Orphan Drug Exclusivity(ODE-492) | Aug 09, 2031 |
Drugs and Companies using PALOPEGTERIPARATIDE ingredient
NCE-1 date: 09 August, 2028
Market Authorisation Date: 09 August, 2024
Treatment: Treatment of hypoparathyroidism in adults
Dosage: SOLUTION
More Information on Dosage
YORVIPATH family patents
34. Zelsuvmi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8282967 | LNHC | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
May, 2026
(6 months from now) | |
| US8956658 | LNHC | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
May, 2026
(6 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9737561 | LNHC | Topical gels and methods of using the same |
Aug, 2030
(4 years from now) | |
| US10376538 | LNHC | Topical gels and methods of using the same |
Aug, 2030
(4 years from now) | |
| US9526738 | LNHC | Topical gels and methods of using the same |
Sep, 2031
(5 years from now) | |
| US9289442 | LNHC | Topical compositions |
Jul, 2032
(6 years from now) | |
| US10265334 | LNHC | Anhydrous compositions |
Jul, 2032
(6 years from now) | |
| US9855211 | LNHC | Topical compositions and methods of using the same |
Feb, 2034
(8 years from now) | |
| US11285098 | LNHC | Topical compositions and methods of using the same |
Feb, 2034
(8 years from now) | |
| US10258564 | LNHC | Topical compositions and methods of using the same |
Nov, 2034
(9 years from now) | |
| US10322081 | LNHC | Topical antiviral compositions and methods of using the same |
Jul, 2035
(9 years from now) | |
| US11040006 | LNHC | Topical antiviral compositions, delivery systems, and methods of using the same |
Jul, 2035
(9 years from now) | |
| US11723858 | LNHC | Topical antiviral compositions, delivery systems, and methods of using the same |
Jul, 2035
(9 years from now) | |
| US10736839 | LNHC | Topical antiviral compositions, delivery systems, and methods of using the same |
Jul, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 05, 2029 |
Drugs and Companies using BERDAZIMER SODIUM ingredient
NCE-1 date: 06 January, 2028
Market Authorisation Date: 05 January, 2024
Treatment: Method of treating skin ailment with nitric oxide releasing macromolecules and hydrophilic gel; Method of application of topical pharmaceutical composition to treat dermatological condition; Method of...
Dosage: GEL
More Information on Dosage
ZELSUVMI family patents